Similar articles

• Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

  Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Bussel JB, et al. Lancet. 2009 Feb 21;373(9664):641-8. doi: 10.1016/S0140-6736(09)60402-5. Lancet. 2009. PMID: 19231632 Clinical Trial.
• [Eltrombopag increases thrombocyte count and reduces the bleeding risk].

  [No authors listed] [No authors listed] Med Monatsschr Pharm. 2007 Oct;30(10):390-1. Med Monatsschr Pharm. 2007. PMID: 17966290 German. No abstract available.
• Sustaining platelet counts in chronic ITP.

  Nurden AT. Nurden AT. Lancet. 2011 Jan 29;377(9763):358-60. doi: 10.1016/S0140-6736(10)61090-2. Epub 2010 Aug 23. Lancet. 2011. PMID: 20739056 No abstract available.
• Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.

  Cook L, Cooper N. Cook L, et al. Drug Des Devel Ther. 2010 Jul 21;4:139-45. doi: 10.2147/dddt.s8601. Drug Des Devel Ther. 2010. PMID: 20689640 Free PMC article. Review.
• Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials.

  Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Elgebaly AS, et al. Clin Appl Thromb Hemost. 2017 Nov;23(8):928-937. doi: 10.1177/1076029616663849. Epub 2016 Aug 29. Clin Appl Thromb Hemost. 2017. PMID: 27572890 Review.